Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Hotung Investment (和通)
29-06-2018, 06:22 PM.
Post: #201
RE: Hotung
Listing of An Investee Company - Foresee Pharmaceuticals Co., Ltd.

Hotung Investment Holdings Limited announced the listing of one of its investee companies, Foresee Pharmaceuticals Co., Ltd., on the Taipei Exchange on 29 June 2018.

The Group had invested in Foresee since February 2016.

Information on Foresee
Foresee is a clinical-stage pharmaceutical company. The core competency of Foresee includes rapid development and commercialization of new drugs using its proprietary drug delivery technology, the Stabilized Injectable Formulation platform (SIF), as well as developing first-in-class New Chemical Entity (NCE) in disease areas of high unmet medical needs.

Based on its core competency, Foresee has developed two global patent protected new drugs, FP-001 and FP-025, currently in clinical development stage. The FP-001 50mg phase 3 registration study in advanced prostate cancer has successfully hit the primary endpoints and another formulation of 25mg is currently on the phase 3 registration trial. The FP-025, a small molecule MMP-12 inhibitor for the treatment of asthma / chronic obstructive pulmonary disease, just launched its phase 2 study in Netherlands.

In 2017, Foresee and Switzerland based pharmaceutical company, Ferring Pharmaceuticals, have entered into an exclusive worldwide development and option agreement to leverage Foresee’s proprietary and unique Stabilized Injectable Formulation platform (SIF) for the development of long duration, controlled release formulations of a peptide therapeutic. Under the terms of the agreement, Ferring will fund the development work and, upon completion, Ferring will have the right to exercise its option and enter into a definitive agreement with Foresee.
=========== Signature ===========
Specuvestor: Asset - Business - Structure.

Find Reply
04-01-2019, 05:13 PM.
Post: #202
Hotung Investment (和通)
A brief write up for Hotung Investment

Indeed huge cash balance (40% of market cap), but there is no recurrent cashflow to support the dividend, so each year dividend will be continuously drawing out from cash reserve. 

Find Reply

Forum Jump:

Users browsing this thread: 1 Guest(s) | Return to Top | Lite (Archive) Mode | RSS Syndication | CONTACT US: | | Share Buy-Back | Disclosure of Interest